Reports
Global Non-Hodgkin’s Lymphoma Treatment Market Share, Size, Growth, Analysis: By Treatment Type: Immunotherapy, Targeted Therapy, Chemotherapy, Others; By Disease Type: B Cell Lymphoma, T Cell Lymphoma; By Diagnosis: Biopsy, Cell and Tissue Study, Blood Tests, Imaging Tests, Others; Regional Analysis; Supplier Landscape; 2023-2031
Global Non-Hodgkin’s Lymphoma Treatment Market Outlook
The global non-Hodgkin’s lymphoma treatment market attained a value of USD 12.54 billion in 2022. The market is expected to grow further at a CAGR of 7.20% during the forecast period of 2023-2031 to attain a value of USD 23 billion by 2031, driven by the rising technological advancement and the increased availability of treatments.
Non-Hodgkin’s Lymphoma Treatment Market: Introduction
Non-Hodgkin's lymphoma is the type of cancer that develops in the white blood cells of the immune system, which are also known as lymphocytes. When these white blood cells start growing abnormally, they start forming tumours throughout the body.
Major sites of these lymph tissue include lymph nodes, spleen, bone marrow, thymus, digestive tract, adenoids, and tonsils, among others. NHL is inclusive of different types of blood cancers. The subtypes can either progress slowly (indolent subtype) or spread rapidly (aggressive subtype). The non-Hodgkin’s lymphoma can be of two types, that is B cells and T cells. B cells are the cells which are responsible for producing antibodies which help in fighting off infections. On the other hand, T cells have different functions, including the role of providing support to the B cells in antibodies production.
While the exact cause of non-Hodgkin’s lymphoma continues to be ambiguous, some of the potential factors responsible for the condition are genetic factors, lifestyle, infections, weak immune system, occupation, and the medical history of the patient as well as their family, among other factors.
The symptoms of the condition are sometimes so common that the patient tends to mistake them for general flu or virus. The signs and symptoms significantly rely on factors like the location of the tumour, its size, and its growth speed. The most common signs and symptoms of the disease include fever, nausea, fatigue, significant weight loss, skin problems like rashes or itchy skin, pain in bones, abdomen, or chest without any reason, severe sweat at night, and swollen lymph nodes, among others.
These symptoms can either happen separately or all at once. For instance, when symptoms like night sweats, severe weight loss, and fever happen together, then these symptoms are clubbed as B symptoms.
Non-Hodgkin’s Lymphoma Treatment Market Segmentations
The market can be categorized into segments like treatment type, disease type, diagnosis, and major regions.
Market Breakup by Treatment Type
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Others
Market Breakup by Disease Type
- B Cell Lymphoma
- T Cell Lymphoma
Market Breakup by Diagnosis
- Biopsy
- Bone Marrow Aspiration and Biopsy
- Excisional or Incisional Biopsy
- Needle Biopsy
- Cell and Tissue Study
- Fluorescence in situ Hybridization
- Polymerase Chain reaction
- Immunophenotyping
- Blood Tests
- Complete Blood Count
- Blood Chemical Test
- Imaging Tests
- Chest X-Ray
- CT Scan
- MRI
- Ultrasound
- Bone Scan
- PET Scan
- Others
Non-Hodgkin's Lymphoma Treatment Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Non-Hodgkin’s Lymphoma Treatment Market Scenario
The growth of the market is likely to grow significantly over the forecast period owing to the rising number of cases amongst children. The rising demand for the treatment market can also be attributed to the rising technological advancements, rising number of approved drugs and treatments, as well as the development of new and advanced drugs.
Globally, North America is anticipated to account for a significant share over the coming years since the region is technologically advances and the awareness about different types of cancer in the region is high. The awareness about the importance of conducting regular health check-ups has also propelled the growth of the market. Other than North America, Europe and Asia Pacific are also likely to witness robust growth in the coming years with the rapidly rising number of cases across these regions.
Non-Hodgkin’s Lymphoma Treatment Market- Epidemiology
The prevalence of the disease is constantly across the globe. The total number of cases in the year 2022 reached around 570,000. Older people are more vulnerable to this condition, especially people belonging to the age group of 65-75; however, it can happen to anyone. Men are more likely to suffer from the disease than women. People who consume immunosuppressant drugs immediately after any organ transplant are also at a higher risk of having this condition.
NHL is a disease which attacks people who have a weaker immune system. Variety of factors could lead to a weaker immune system. These factors include inherited immunity ailments like Wiskott-Aldrich syndrome and hypogammaglobulinemia, autoimmune conditions like HIV/ AIDS, psoriasis, arthritis, or Sjögren syndrome, Helicobacter pylori infection, and Epstein-Barr virus infection or Human T-lymphotropic virus type I.
Non-Hodgkin’s Lymphoma Treatment Market- Therapeutic Landscape
Various treatment methods are used for NHL including radiation therapy, chemotherapy, immunotherapy, targeted therapy, Plasmapheresis, antibiotic therapy, and surgery, among others. The three major treatment methods covered in this report include the following:
Immunotherapy- This treatment uses the patient’s immunity system to fight the cancer cells. Medications are used to boost the immunity system of the patient to kill the cancer cells, which also helps in preventing further growth of cancer cells. Immunomodulators like Lenalidomide are used to treat adult non-Hodgkin lymphoma. Immunotherapy also includes the use of CAR T-cell therapy.
Targeted Therapy- This therapy uses certain drugs to attack the cancer cells. Some of the prominent therapies under this treatment type include proteasome inhibitor therapy, monoclonal antibody therapy, and kinase inhibitor therapy.
- Proteasome Inhibitor Therapy: The inhibition of proteasome might help in killing the cancer cells. Drugs like Bortezomib or ixazomib are used in this treatment method.
- Monoclonal Antibody Therapy: It comprises the use of drugs like Rituximab, Mogamulizumab, Brentuximab vedotin, Obinutuzumab, Tafasitamab, Polatuzumab vedotin, Pembrolizumab, and Yttrium Y 90-ibritumomab tiuxetan, among others.
- Kinase Inhibitor Therapy: This therapy helps in inhibiting the growth of protein cells which might be contributing to the growth of cancer cells in the body. It includes the use of drugs like Copanlisib, acalabrutinib, zanubrutinib, and Ibrutinib.
- Other treatments included in targeted therapy are Histone methyltransferase inhibitor therapy and B-cell lymphoma-2 (BCL-2) inhibitor therapy.
Chemotherapy- This treatment includes the use of drug which is given either orally or through drip or injections to the patient. In some cases, the patient might require a combination of both. To avoid the risk of cancer reaching the brain, these injections might be injected directly into the cerebrospinal fluid, that is around the spine. Chemotherapy is given in an interval of months, depending on the patient’s response to the drugs.
No matter which method of treatment is opted for the patient, these drugs are extremely strong and lead to sever side effects. Some of these toxic side effects also include loss of fertility, paralysis, different types of cancer, and baldness, among others.
Key Players in the Global Non-Hodgkin’s Lymphoma Treatment Market
The major companies working on the drugs and treatment of the condition, and investing in the clinical trials include the following:
- Eli Lilly and Company
- Corvus Pharmaceuticals
- Rafael Pharmaceuticals
- AbbVie
- ADC Therapeutics
- Genetech
- Tessa Therapeutics
- Bristol Myers Squibb
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by Diagnosis |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Non-Hodgkin’s Lymphoma Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.2.2 Cost of Treatment
6.2.3 Regulatory Framework
6.2.3.1 Regulatory Overview
6.2.3.1.1 US FDA
6.2.3.1.2 EU EMA
6.2.3.1.3 INDIA CDSCO
6.2.3.1.4 JAPAN PMDA
6.2.3.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop- out Analysis
7.3 Awareness and Prevention Gaps
8 Global Non-Hodgkin’s Lymphoma Treatment Market
8.1 Global Non-Hodgkin’s Lymphoma Treatment Market Overview
8.2 Global Non-Hodgkin’s Lymphoma Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Historical Non-Hodgkin’s Lymphoma Market Value (2016-2022)
8.2.1.2 Global Forecast Non-Hodgkin’s Lymphoma Market Value (2023-2031)
8.3 Global Non-Hodgkin’s Lymphoma Treatment Market by Treatment Type
8.3.1 Market Overview
8.3.1.1 Immunotherapy
8.3.1.2 Targeted Therapy
8.3.1.3 Chemotherapy
8.3.1.4 Others
8.4 Global Non-Hodgkin’s Lymphoma Treatment Market by Disease Type
8.4.1 Market Overview
8.4.1.1 B Cell Lymphoma
8.4.1.2 T Cell Lymphoma
8.5. Global Non-Hodgkin’s Lymphoma Treatment Market by Diagnosis
8.5.1 Market Overview
8.5.1.1 Biopsy
8.5.1.1.1 Bone Marrow Aspiration and Biopsy
8.5.1.1.2 Excisional or Incisional Biopsy
8.5.1.1.3 Needle Biopsy
8.5.1.2 Cell and Tissue Study
8.5.1.2.1 Fluorescence in situ Hybridization
8.5.1.2.2 Polymerase Chain reaction
8.5.1.2.3 Immunophenotyping
8.5.1.3 Blood Tests
8.5.1.3.1 Complete Blood Count
8.5.1.3.2 Blood Chemical Test
8.5.1.4 Imaging Tests
8.5.1.4.1 Chest X-Ray
8.5.1.4.2 CT Scan
8.5.1.4.3 MRI
8.5.1.4.4 Ultrasound
8.5.1.4.5 Bone Scan
8.5.1.4.6 PET Scan
8.5.1.5 Others
8.6 Global Non-Hodgkin’s Lymphoma Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Non-Hodgkin’s Lymphoma Treatment Market
9.1 United States of America
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2 Canada
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
10 Europe Non-Hodgkin’s Lymphoma Treatment Market
10.1 United Kingdom
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2 Germany
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 France
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 Italy
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
11 Asia Pacific Non-Hodgkin’s Lymphoma Treatment Market
11.1 China
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 Japan
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 India
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 ASEAN
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 Australia
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
12 Latin America Non-Hodgkin’s Lymphoma Treatment Market
12.1 Brazil
12.1.1 Historical Trend (2016-2022)
12.1.2 Forecast Trend (2023-2031)
12.2 Argentina
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Mexico
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
13 Middle East and Africa Non-Hodgkin’s Lymphoma Treatment Market
13.1 Saudi Arabia
13.1.1 Historical Trend (2016-2022)
13.1.2 Forecast Trend (2023-2031)
13.2 United Arab Emirates
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 Nigeria
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 South Africa
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
14 Global Non-Hodgkin’s Lymphoma Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Eli Lilly and Company
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Corvus Pharmaceuticals
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Rafael Pharmaceuticals
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 AbbVie
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 ADC Therapeutics
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Genetech
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Tessa Therapeutics
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Bristol Myers Squibb
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
16 Non-Hodgkin’s Lymphoma Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2022, the market attained a value of nearly USD 12.54 billion.
The market is projected to grow at a CAGR of 7.20% during the forecast period of 2023-2031.
The market is estimated to witness robust growth during the forecast period of 2022-2031 to reach a value of USD 23 billion by 2031.
The growth of the market is driven by the rising prevalence of the disease, availability of treatment, and the technological advancement in the healthcare sector.
The rising awareness about the importance of early detection acts as a key trend for the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The treatment types include immunotherapy, targeted therapy, and chemotherapy, among others.
The disease can be divided into two types, B-cell and T-cell lymphoma.
The diagnosis methods include Biopsy, Cell and Tissue Study, Blood Tests, and imaging types, among others.
The major players in the market are Eli Lilly and Company, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, and Bristol Myers Squibb.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$3499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER